ACUVAIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7842714 | ABBVIE | Ketorolac tromethamine compositions for treating ocular pain |
Aug, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8992952 | ABBVIE | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug, 2024
(3 months from now) | |
| US8512717 | ABBVIE | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Mar, 2028
(3 years from now) | |
| US9192571 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Mar, 2028
(3 years from now) | |
Acuvail is owned by Abbvie.
Acuvail contains Ketorolac Tromethamine.
Acuvail has a total of 4 drug patents out of which 0 drug patents have expired.
Acuvail was authorised for market use on 22 July, 2009.
Acuvail is available in solution/drops;ophthalmic dosage forms.
The generics of Acuvail are possible to be released after 15 August, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 22, 2012 |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage
ACUVAIL family patents
